Published in Gut on January 20, 2012
Retracted Deficiency of G-protein-coupled bile acid receptor Gpbar1 (TGR5) enhances chemically induced liver carcinogenesis. Hepatology (2013) 2.16
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol (2013) 1.80
Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol (2015) 1.54
Immune regulation by atypical chemokine receptors. Nat Rev Immunol (2013) 1.17
Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy. Mol Ther (2014) 0.93
Role of lymphocytes in liver cancer. Oncoimmunology (2013) 0.93
Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front Immunol (2014) 0.92
The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. Natl Sci Rev (2014) 0.91
Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection. Oncotarget (2015) 0.89
Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol (2012) 0.87
Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut (2015) 0.86
Assessment of hemodynamics in a rat model of liver cirrhosis with precancerous lesions using multislice spiral CT perfusion imaging. Biomed Res Int (2013) 0.83
Inflammatory models drastically alter tumor growth and the immune microenvironment in hepatocellular carcinoma. Sci Bull (Beijing) (2015) 0.78
Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol (2017) 0.78
Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. J Hepatol (2016) 0.77
Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner. Eur J Immunol (2015) 0.77
Distinct anti-tumoral functions of adaptive immune cells in liver cancer. Oncoimmunology (2012) 0.76
Balance of inflammatory pathways and interplay of immune cells in the liver during homeostasis and injury. EXCLI J (2014) 0.76
Loss of Dicer1 impairs hepatocyte survival and leads to chronic inflammation and progenitor cell activation. World J Gastroenterol (2015) 0.76
Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis. World J Gastrointest Pathophysiol (2015) 0.76
IL6 mediated inflammatory loop reprograms normal to EMT(+) metastatic CSCs in pre-neoplastic liver of TGFβ deficient β2SP(+/-) mice. Hepatology (2016) 0.75
EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway. J Exp Clin Cancer Res (2016) 0.75
Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection. J Cancer (2017) 0.75
Hepatoma cell-derived leptin downregulates the immunosuppressive function of regulatory T-cells to enhance the anti-tumor activity of CD8(+) T-cells. Immunol Cell Biol (2015) 0.75
Protective Effect of Boiled and Freeze-dried Mature Silkworm Larval Powder Against Diethylnitrosamine-induced Hepatotoxicity in Mice. J Cancer Prev (2016) 0.75
Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes. Cancer Res (2016) 0.75
Role of the BrafV637E mutation in hepatocarcinogenesis induced by treatment with diethylnitrosamine in neonatal B6C3F1 mice. Mol Carcinog (2016) 0.75
Immune surveillance of liver cancer in non-alcoholic fatty liver disease: excess lipids cause CD4 T-cells loss and promote hepatocellular carcinoma development. Hepatobiliary Surg Nutr (2016) 0.75
Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-κB activation. Oncotarget (2016) 0.75
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
RAG-1-deficient mice have no mature B and T lymphocytes. Cell (1992) 20.97
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell (2007) 5.91
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol (2007) 5.28
Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science (1999) 4.77
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet (2004) 3.97
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. J Exp Med (2006) 3.43
NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2011) 3.28
TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell (2010) 3.25
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology (2009) 3.20
Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol (2011) 3.12
The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol (2005) 2.98
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity (2003) 2.63
BLNK: a central linker protein in B cell activation. Immunity (1998) 2.59
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45
Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol (1994) 2.26
Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol (2008) 2.26
Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med (2010) 2.17
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut (2011) 2.06
Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One (2010) 1.94
Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61
The fractalkine receptor CX₃CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology (2010) 1.59
Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut (2011) 1.56
Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm Allergy Drug Targets (2009) 1.52
Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol (2009) 1.51
The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest (2007) 1.46
Chemokines in liver inflammation and fibrosis. Semin Liver Dis (2010) 1.42
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res (2010) 1.41
Phospholipase C-gamma2 is essential for NK cell cytotoxicity and innate immunity to malignant and virally infected cells. Blood (2005) 1.31
Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology (2012) 1.25
PLC-gamma2 is essential for formation and maintenance of memory B cells. J Exp Med (2009) 1.17
Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma? Oncotarget (2010) 1.03
Preneoplastic and neoplastic progression during hepatocarcinogenesis in mice injected with diethylnitrosamine in infancy. Environ Health Perspect (1983) 1.03
Immune responses in hepatocellular carcinoma. Dig Dis (2010) 0.97
iCOD: an integrated clinical omics database based on the systems-pathology view of disease. BMC Genomics (2010) 0.95
Innovative immunohistochemistry identifies MMP-9 expressing macrophages at the invasive front of murine HCC. World J Hepatol (2010) 0.95
Tetraspanins in the humoral immune response. Biochem Soc Trans (2011) 0.91
B cells and macrophages in cancer: yin and yang. Nat Med (2011) 0.91
Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. Int J Clin Oncol (2010) 0.90
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature (2010) 15.28
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest (2007) 9.09
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 8.25
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
Origin of the lamina propria dendritic cell network. Immunity (2009) 5.95
Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell (2007) 5.91
Langerhans cells arise from monocytes in vivo. Nat Immunol (2006) 5.46
Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol (2006) 5.00
The origin and development of nonlymphoid tissue CD103+ DCs. J Exp Med (2009) 4.79
Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology (2010) 4.72
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell (2010) 3.25
The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest (2005) 3.22
A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell (2012) 3.21
Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology (2009) 3.20
Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med (2004) 3.17
Comparison of gene expression profiles between human and mouse monocyte subsets. Blood (2009) 3.15
STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology (2006) 3.05
Blood monocyte subsets differentially give rise to CD103+ and CD103- pulmonary dendritic cell populations. J Immunol (2008) 3.04
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A (2006) 3.00
A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol (2013) 2.98
The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol (2005) 2.98
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J (2002) 2.96
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest (2010) 2.87
Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res (2007) 2.85
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A (2004) 2.77
Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol (2010) 2.71
Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J Exp Med (2004) 2.68
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity (2006) 2.62
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet (2007) 2.54
Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53
CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood (2008) 2.52
Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology (2014) 2.45
Stress-induced production of chemokines by hair follicles regulates the trafficking of dendritic cells in skin. Nat Immunol (2012) 2.40
Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A (2003) 2.34
Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol (2009) 2.27
Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. J Hepatol (2003) 2.24
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet (2005) 2.20
Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest (2005) 2.20
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol (2009) 2.17
Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med (2010) 2.17
Modulation of dendritic cell trafficking to and from the airways. J Immunol (2006) 2.17
Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J Clin Invest (2006) 2.13
The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol (2007) 2.13
Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity (2013) 2.08
The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C. Hepatology (2011) 2.08
CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J Clin Invest (2011) 2.08
Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut (2011) 2.06
Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation (2007) 2.06
Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology (2011) 2.05
A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci (2013) 2.03
Cytokine regulation of pro- and anti-apoptotic genes in rat hepatocytes: NF-kappaB-regulated inhibitor of apoptosis protein 2 (cIAP2) prevents apoptosis. J Hepatol (2002) 1.99
First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet (2008) 1.98
IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol (2008) 1.97
Involvement of TRAIL and its receptors in viral hepatitis. FASEB J (2002) 1.97